The Vitamin D Analog 1α,25-Dihydroxy-2β-(3-Hydroxypropyloxy) Vitamin D3 (Eldecalcitol) is a Potent Regulator of Calcium and Phosphate Metabolism

  • Alex J. BrownEmail author
  • Cynthia S. Ritter
Original Research


The vitamin D analog 1α,25-dihydroxy-2β-(3-hydroxypropyloxy)vitamin D3 (ED-71 or eldecalcitol) has been developed for treatment of osteoporosis, but its effects on mineral metabolism have not been investigated in detail. In the present study, we compared the effects of eldecalcitol and calcitriol on calcium (Ca) and phosphate (Pi) handling in rats. Oral administration of eldecalcitol (0, 7.5, 20, or 50 pmol) q.o.d. for 2 weeks dose-dependently increased ionized Ca, intestinal Ca absorption, and urinary Ca excretion, while these doses of calcitriol had no significant effects. The highest dose of eldecalcitol did not alter serum Pi but stimulated both intestinal Pi absorption and urinary Pi excretion; the latter was attributable, in part, to increased serum FGF-23. The effects of high-dose eldecalcitol on Ca and Pi absorption and urinary excretion and FGF-23 persisted for several days following cessation of treatment. The higher potency of eldecalcitol on Ca and Pi handling was also observed in parathyroidectomized rats infused with PTH, excluding a role for differential regulation of PTH. Direct measurement of duodenal Ca absorption by the in situ loop method confirmed the higher potency of eldecalcitol in this segment via induction of TRPV6. These studies indicated that with chronic administration eldecalcitol is more potent than calcitriol at stimulating intestinal absorption of Ca and Pi, as well as FGF-23. The mechanisms responsible for the higher potency of eldecalcitol are speculated to be its higher vitamin D-binding protein (DBP) affinity and resistance to metabolism.


Intestinal mineral absorption Mineral and electrolyte metabolism PTH/PTHrP Vitamin D 



This work was supported by a research grant from Chugai Pharmaceutical. The authors thank Jane Boudreaux for assistance with the in vivo studies.


  1. 1.
    Matsumoto T, Kubodera N (2007) ED-71, a new active vitamin D3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J Steroid Biochem Mol Biol 103(3–5):584–586PubMedCrossRefGoogle Scholar
  2. 2.
    Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Nishii Y (1991) A novel synthetic vitamin D3 analogue, 2-beta-(3-hydroxypropoxy)-calcitriol (ED-71): its biological activities and pharmacological effects on calcium metabolism. Contrib Nephrol 91:116–122PubMedGoogle Scholar
  3. 3.
    Tsurukami H, Nakamura T, Suzuki K, Sato K, Higuchi Y, Nishii Y (1994) A novel synthetic vitamin D analogue, 2 beta-(3-hydroxypropoxy)1alpha, 25-dihydroxyvitamin D3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 54(2):142–149PubMedCrossRefGoogle Scholar
  4. 4.
    Uchiyama Y, Higuchi Y, Takeda S, Masaki T, Shira-Ishi A, Sato K, Kubodera N, Ikeda K, Ogata E (2002) ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30:582–588PubMedCrossRefGoogle Scholar
  5. 5.
    Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T (2005) A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 90(9):5031–5036PubMedCrossRefGoogle Scholar
  6. 6.
    Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Takita Y, Nishii Y (1989) Regulatory activities of 2beta-(3-hydroxypropoxy)-1alpha, 25-dihydroxyvitamin D3, a novel synthetic vitamin D3 derivative, on calcium metabolism. Biochem Biophys Res Commun 163(3):1444–1449PubMedCrossRefGoogle Scholar
  7. 7.
    Hatakeyama S, Nagashima S, Imai N, Takahashi K, Ishihara J, Sugita A, Nihei T, Saito H, Takahashi F, Kubodera N (2007) Synthesis and biological evaluation of a 3-position epimer of 1alpha, 25-dihydroxy-2beta-(3-hydroxypropoxy)vitamin D3 (ED-71). J Steroid Biochem Mol Biol 103(3–5):222–226PubMedCrossRefGoogle Scholar
  8. 8.
    Flanagan JN, Zheng S, Chiang KC, Kittaka A, Sakaki T, Nakabayashi S, Zhao X, Spanjaard RA, Persons KS, Mathieu JS, Holick MF, Chen TC (2009) Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha, 25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 29(9):3547–3553PubMedGoogle Scholar
  9. 9.
    Saito N, Suhara Y, Abe D, Kusudo T, Ohta M, Yasuda K, Sakaki T, Honzawa S, Fujishima T, Kittaka A (2009) Synthesis of 2alpha-propoxy-1alpha, 25-dihydroxyvitamin D3 and comparison of its metabolism by human CYP24A1 and rat CYP24A1. Bioorg Med Chem 17(13):4296–4301PubMedCrossRefGoogle Scholar
  10. 10.
    Finch JL, Brown AJ, Mori T, Nishii Y, Slatopolsky E (1992) Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1, 25-(OH)2D3. J Bone Miner Res 7(7):835–839PubMedCrossRefGoogle Scholar
  11. 11.
    Kollenkirchen U, Fox J, Walters MR (1991) Normocalcemia without hyperparathyroidism in vitamin D-deficient rats. J Bone Miner Res 6(3):273–278PubMedCrossRefGoogle Scholar
  12. 12.
    Brown AJ, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E (1993) The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133(3):1158–1164PubMedCrossRefGoogle Scholar
  13. 13.
    Brown AJ, Ritter CS, Holliday LS, Knutson JC, Strugnell SA (2004) Tissue distribution and activity studies of 1,24-dihydroxyvitamin D2, a metabolite of vitamin D2 with low calcemic activity in vivo. Biochem Pharmacol 68(7):1289–1296PubMedCrossRefGoogle Scholar
  14. 14.
    Brown AJ, Finch JL, Takahashi F, Slatopolsky E (2000) The calcemic activity of 19-nor-1,25(OH)2D2 decreases with duration of treatment. J Am Soc Nephrol 11:2088–2094PubMedGoogle Scholar
  15. 15.
    Mizobuchi M, Ritter CS, Krits I, Slatopolsky E, Sicard G, Brown AJ (2009) Calcium-sensing receptor expression is regulated by glial cells missing-2 in human parathyroid cells. J Bone Miner Res 24(7):1173–1179PubMedCrossRefGoogle Scholar
  16. 16.
    Harada S, Takeda S, Uno A, Takahashi F, Saito H (2010) Eldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivo. J Steroid Biochem Mol Biol 121(1–2):281–283PubMedCrossRefGoogle Scholar
  17. 17.
    Slatopolsky E, Finch J, Ritter C, Takahashi F (1998) Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis 32(Suppl 2):S40–S47PubMedCrossRefGoogle Scholar
  18. 18.
    Brown AJ, Finch J, Slatopolsky E (2002) Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clin Med 139:279–284PubMedCrossRefGoogle Scholar
  19. 19.
    Halloran BP, De Luca HF (1981) Intestinal calcium transport: evidence for two distinct mechanisms of action of 1,25-dihydroxyvitamin D3. Arch Biochem Biophys 208(2):477–486PubMedCrossRefGoogle Scholar
  20. 20.
    Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R, Carmeliet G (2001) Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci USA 98(23):13324–13329PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Renal DivisionWashington University School of MedicineSt. LouisUSA

Personalised recommendations